Annals of the American Thoracic Society · 2020 · 18 citations · 13 references
Social SciencesHealth PolicyHealth EconomicsHealthcare EconomicsPharmacoeconomic ModelingChronic Disease BurdenEconomic EvaluationHealth Care CostsHealthcare Cost AnalysisLife ExpectancyOutcome ValuationChronic Disease Cost AnalysisDisease Cost Of IllnessEconomic Burden Of DiseaseEconomic Burden Of IllnessLifetime AnalysisLifetime Cost AnalysisLifetime EstimationLifetime Healthcare Cost Estimation
Abstract Rationale Approximately 8% of the U.S. population suffers from asthma, a chronic condition. It poses a substantial economic burden to society in the form of lost productivity and healthcare costs. Objectives We use the Medical Expenditure Panel Survey 2002–2010 to quantify the lifetime costs of asthma at each age, the impact of adult asthma on earnings and choice of occupation, and the impact of childhood asthma on parental income. Methods We developed a framework to estimate the present discounted value of the cumulative lifetime asthma-related healthcare costs and lost productivity experienced by an individual after onset. This approach allows for age- and asthma duration-related variability in annual costs as well as for the intermittent nature of asthma symptoms. Results Estimated asthma-related annual healthcare expenditures across all life stages are $700–$2,200 (2010 U.S. dollars). Lost annual earnings among individuals aged 30–49 are over $4,000 (2010 U.S. dollars). The present discounted value of the cumulative lifetime healthcare costs and lost productivity for a new case of asthma is estimated at $36,500 using the 3% discount rate (2010 U.S. dollars). Conclusions The economic burden of asthma is substantial and larger than previously estimated, reflecting expenditures on treatment and lost earnings.
13
Rafael Lozano, Mohsen Naghavi, Kyle J Foreman et al. · The Lancet · 2012 · 14.3K citations · Full text
Generalized, Linear, and Mixed Models
Mark Von Tress · Technometrics · 2003 · 520 citations